Will ditching Solvency II deliver a Brexit dividend or disaster for insurers?

tearing regulations

Analysis: Rachel Gordon explores whether ditching Solvency II will free up billions of capital for insurers or ramp up risk and weaken consumer protection.

When Chancellor of the Exchequer Jeremy Hunt’s first Autumn Statement delivered the overhaul of Solvency II that insurers had long lobbied for, providers were swift to rejoice and promise to plough

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@postonline.co.uk or view our subscription options here: http://subscriptions.postonline.co.uk/subscribe

You are currently unable to copy this content. Please contact info@postonline.co.uk to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Insurance Post? View our subscription options

How Trump’s tariffs shook up insurers’ investment books

Darren Bustin, global head of solutions capabilities and insurance solutions at Schroders, has revealed how regulatory changes, Labour’s growth agenda plus US President Donald Trump’s trade tariffs have impacted general insurers’ investment books.

Rachel Lam named interim ombudsman MD

Rachel Lam is now interim managing ombudsman director of the Financial Ombudsman Service, as Jenny Simmonds and James Dipple-Johnstone temporarily step into the shoes of Abby Thomas.

Why too little red pen in board reports is a red flag

After the FCA raised concerns about non-financial misconduct, Sophie Espinasse, head of client learning at Konexo, warns too little red pen in board reports should be a red flag to them as they seek to crack down on bad apples in their organisations.

Most read articles loading...

You need to sign in to use this feature. If you don’t have an Insurance Post account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here